News | April 01, 2021
Piramal Pharma to acquire 100% stake in Hemmo for Rs 775 Cr
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Tiger can no longer make an important biotin intermediate using a DSM patented process.
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Subscribe To Our Newsletter & Stay Updated
